drugset / Trial / NCT05177939

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

NCT05177939

Phase 3 Unknown 40 enrolled Nihon Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.

Timeline

Start
2022-03-03
Primary completion
2024-05-31
Completion
2024-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic
Comparator Methylprednisolone Other / unclassified